



i m m a t i c s

/ immatics receives €40 million in second round of funding / Largest private biotech financing round in Germany since 2001

Tuebingen, Germany, February 8, 2007. immatics biotechnologies GmbH, a biopharmaceutical company that specializes in the development of peptide-based immunotherapeutic substances for the treatment of cancers, is receiving €40 million in a second round of financing. This marks the closing of the largest private biotech financing round in Germany since the year 2001 for this Tuebingen-based company. The investors – in addition to the existing consortium under the co-lead of Wellington Partners and 3i – include Dietmar Hopp as the new lead investor (through DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG), as well as the National Technology Enterprises Company (NTEC) and KfW as new co-investors. In early 2004, immatics had already concluded one of the largest Series A rounds of financing ever for a German biotech company, raising over €14 million.

“This new funding will not only enable us to pursue two parallel Phase II clinical studies on our two most highly developed product candidates, but will also allow us to further expand our pipeline,” notes immatics Chief Scientific Officer and co-founder Dr. Harpreet Singh. Currently under clinical development is therapeutic vaccine IMA901 for the treatment of renal cell cancer; IMA910 for the treatment of intestinal (colorectal) cancer is scheduled to follow this year. In late September 2006, and thus less than three years after beginning early preclinical development, immatics had successfully concluded an international Phase I study on IMA901.

immatics’ product candidates are based upon so-called tumor-associated peptides (TUMAPs), which specifically stimulate the immune system against cancer cells. The company’s proprietary technology can also be used to quickly identify and validate further new peptide-based active ingredients for the treatment of all major cancers.

In addition to the existing investor consortium, immatics’ technology and rapidly growing pipeline also convinced SAP co-founder Dietmar Hopp’s DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG. “immatics is one of the most promising German biotech companies; in addition to innovative technologies, it also possesses a highly promising pipeline as well as a high level of entrepreneurial competence,”

summarizes Dr. Friedrich von Bohlen und Halbach, the managing director of Dievini GmbH & Co. KG, which advises and supports Dietmar Hopp in his life science investments. 3i partner Dr. Klaus Stöckemann stresses immatics' market potential: "The immatics technology enables therapeutic vaccines to be developed for numerous
35 cancers. This enables the company to address very large markets with annual revenues of over a billion euros."

Prof. Erich Schlick, a General Partner at Wellington Partners, emphasizes: "This round of financing demonstrates the rapidly growing importance of new immunotherapeutic vaccines in oncology and also shows just how much potential exists in German
40 biotechnology companies."

The new financing will provide sufficient funding for immatics to conclude its two planned Phase II studies on its own and additionally ready clinical studies for further
45 projects. The immatics pipeline currently consists of four projects.

About immatics:

immatics (www.immatics.com) is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product candidates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 – and thus less than
50 three years after the conclusion of the first round of funding totaling €14 million – the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immunotherapeutic substances for cancer therapy, are presently undergoing preclinical development
55 and will serve as the basis for a rapidly expanding product pipeline.

Formed in the year 2000 as a spin-off from the Institute of Immunology at the University of Tübingen, immatics today employs a staff of 40 people. The members of immatics' Supervisory Board include the head of the institute, Hans-Georg Rammensee, as well as Actelion co-founder Thomas Widmann, the former global head of regulatory affairs at Bayer AG, Ulrich
60 Granzer, and GPC Biotech CSO Sebastian Meier-Ewert."

About Dievini advisors in health sciences GmbH & Co KG

65 Heidelberg-based Dievini advisors in health sciences GmbH & Co. KG advises and supports Dietmar Hopp in selecting, structuring and accompanying his Life Science investments.

Dievini was formed in 2005 by entrepreneur Dr. Friedrich von Bohlen und Halbach and attorney at law Professor Dr. Christof Hettich. Working together with experts from the fields of medicine, biotechnology and finance, Dievini reviews and analyzes companies, recommends
70 and structures investments, conducts them and in individual cases accompanies and supports the companies in their corporate and business development.

75 For the past several years, Dietmar Hopp, co-founder, former chief executive officer and chairman of the supervisory board of SAP, has been investing in Life Sciences, specifically in the fields of biopharmacy and biotechnology. In addition to his focuses on the fields of cancer, the central nervous system, the cardiovascular system and information-based medicine, he also has a further, regional focus: More than half of the companies in which he is invested are headquartered in Heidelberg or the immediate vicinity. Dietmar Hopp's investments are entrepreneurial in nature, and he is usually the largest single shareholder. His current investments include AC Immune S.A., Apogenix GmbH, Cosmo S.p.A., Curacyte AG, Curevac GmbH, Cytonet GmbH, Febit GmbH, GPC Biotech AG, Heidelberg Pharma AG, Joimax GmbH, Life Biosystems AG, Novalig GmbH, Sygnis Pharma AG and Willex AG.

85 **About 3i**

85 3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital and Venture Capital and invest across Europe, in the United States and in Asia. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business. These underpin the value that we deliver to our portfolio and to our shareholders.

90 3i's Venture Capital partners focus on investing in scaleable seed and start-up and early-stage technology and healthcare businesses on a global basis. The business currently manages investments across Europe, US, Asia and Israel. 3i VC plans to invest \$1.5bn funds over the next five years in ambitious companies in three main areas: healthcare (medtech and biotech), consumer IT (telecomms, Internet, media and electronics) and the clean technology sector.

95 Recent investments include Glucon, Healthcare Brands International, TransMedics, Zonare, Small Bone Innovations, Carmel Pharma, Endosense and Triage Wireless with successful trade sales for Domantis, SBL Vaccines, KuDOS Pharmaceuticals, Arakis, NeoPharma, PHARMetrics, SpineNext and Arexis and IPOs for ProStrakan, Arpida, Paion, Jerini, Epigenomics, Phoqus and Ardana and historically 3i has backed such successes as Actelion, NovusPharma, Biotalia and others. For more information, go to: www.3i.com

105 **About Wellington Partners**

105 Wellington Partners (www.wellington-partners.com) ranks among the most successful pan-European venture capital firms. With € 500 million under management, the firm invests across Europe into opportunities that have the potential to become global leaders, mostly in the areas of information technology, media convergence and life science. Since 1991, Wellington has built up a worldwide network to help its entrepreneurs build companies on a global scale

110 Wellington Partners has invested in 90 companies in Europe and Israel, including publicly traded Actelion, Wavelight and XING, successful privately held companies like Alando (acquired by eBay) and Grandis (acquired by Novartis) and current portfolio companies like immatics, mtm laboratories and Trigen.

115 **For further information**

immatics biotechnologies GmbH
Dr. Niels Emmerich
Paul-Ehrlich-Straße 15
D-72076 Tübingen
120 Tel. +49 (0)7071-565125-0
emmerich@immatics.com